Cargando…

SUN-391 Denosumab Treatment of Patients with Osteoporosis and Idiopathic Hypercalciuria

Background: Idiopathic hypercalciuria (IHC) is associated with reduced bone mineral density (BMD) and higher risk of osteoporotic fractures. Denosumab is a RANK-ligand inhibitor that prevents osteoporosis-related fractures. No previous published studies have specifically evaluated denosumab treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Winston S, Chu, James W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Bone and Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207871/ http://dx.doi.org/10.1210/jendso/bvaa046.1275

Ejemplares similares

Impact of Thyroid Disease on Bone Mineral Density Preservation in Patients With Osteoporosis and Idiopathic Hypercalciuria
por: Chu, James W
Publicado: (2021)

ODP595 Case Series Of Idiopathic Hypercalciuria And Secondary Osteoporosis
por: Mirza, Fayal, et al.
Publicado: (2022)

SUN-512 Denosumab Improves Trabecular but Not Cortical Bone Osteoporosis in a Patient with Refractory Primary Hyperparathyroidism
por: Alhassan, Sharifa, et al.
Publicado: (2019)

SUN-514 Severe Hypophosphatemia and Worsening Secondary Hyperparathyroidism Following Treatment with Denosumab
por: Adepoju, Yewande, et al.
Publicado: (2019)

SUN-513 Parathyromatosis: A Case of Stubborn Hypercalcemia Treated with Denosumab
por: Ventura, Kenilia, et al.
Publicado: (2019)

SUN-377 Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Real World, Prospective Observational Study
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

MON-391 Implementation of an Osteoporosis Risk Assessment Instrument (ORAI) to Increase Referral Rates for DEXA Scanning in the Primary Care Setting
por: Saatciler, Eda, et al.
Publicado: (2020)

An Uncommon Cause of Hypomagnesemia With Hypercalciuria and Nephrocalcinosis in a Young Woman
por: Rudovich, Natalia N, et al.
Publicado: (2021)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

MON-514 Bone Density Yo-yo In A Patient With Severe Hypercalciuria
por: Thakkar, Aditi, et al.
Publicado: (2019)

SUN-396 Denosumab Preserves Bone Mineral Density at the Knee in Persons with Subacute Spinal Cord Injury
por: Bauman, William Alan, et al.
Publicado: (2020)

Low Phosphate Diet Exacerbates Hypercalciuria in the Jimbee Mouse Model of SGLT2 Loss-of Function
por: Thrailkill, Kathryn M, et al.
Publicado: (2021)

SAT-499 Denosumab for Treatment of Hypercalcemia in Myelofibrosis
por: Wong, Beatrice, et al.
Publicado: (2019)

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

SUN-389 Trends in Osteoporosis Treatment Uptake and Persistence Among Postmenopausal Women in the U.S., 2010–2015
por: Kim, Min, et al.
Publicado: (2020)

SUN-374 Decisions to Accept or Decline Pharmacologic Osteoporosis Therapy After Attending a Novel Patient-Centred Educonsult Program for Osteoporosis (PEP-OP)
por: Liu, Crystal Sixian, et al.
Publicado: (2020)

SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis
por: Yavropoulou, Maria, et al.
Publicado: (2020)

MON-517 Treatment of Gorham-Stout Disease with Combination Sirolimus and Denosumab
por: Hartley, Iris, et al.
Publicado: (2019)

SUN-380 Opportunistic Screening with Abdominal CT in Patients with Diabetes Can Identify Those at High Risk of Osteoporosis and Osteopenia
por: Jain, Rajesh, et al.
Publicado: (2020)

MON-356 Atypical Femur Fracture with Denosumab
por: Mirza, Faryal S, et al.
Publicado: (2020)

ODP085 Denosumab Induced Severe Hypophosphatemia
por: Del Mar Morales Hernandez, Maria, et al.
Publicado: (2022)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

PSAT197 Treatment of Paget's Disease of the Skull With Denosumab: A Case Report
por: Torfah, Maisoon, et al.
Publicado: (2022)

Denosumab Induced Severe Hypocalcemia in a Patient With Metastatic Prostate Cancer
por: Naher, Kamrun, et al.
Publicado: (2021)

SAT-509 Denosumab Use in Tertiary Hiperparathyroidism with Fracture
por: Coy, Andres, et al.
Publicado: (2019)

SAT258 Successful Treatment Of Adult T-cell Leukemia-lymphoma Induced Hypercalcemia With Denosumab
por: Yuksel, Simge, et al.
Publicado: (2023)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

RF18 | PMON103 Hypercalciuria in Young Adults With Primary Hyperparathyroidism Is Less Likely to Resolve After a Successful Parathyroidectomy Compare to Older Adults
por: Ayutyanont, Napatkamon, et al.
Publicado: (2022)

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020)

Denosumab Induced Severe Prolonged Hypocalcemia in Metastatic Prostate Cancer
por: Mehmood, Hassan, et al.
Publicado: (2021)

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

OR01-5 Transition From Low Dose Denosumab 30mg to IV Zoledronic Acid: Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Prospective Observational Study
por: Ibrahim, Quazi, et al.
Publicado: (2022)

SUN-376 A Quality Improvement Project on Identification and Management of Primary Hyperparathyroidism in Patients Who Present with Osteoporosis to Reduce Morbidity from Bone Disease
por: Hatta, Sharifah Faradila Wan Muhamad, et al.
Publicado: (2020)

MON-337 Peripheral Neurological Complications in Pregnancy- Is Idiopathic Transient Osteoporosis of Pregnancy Concerning?
por: Aljaberi, Asma Khaled, et al.
Publicado: (2020)

SAT-391 Safety and Efficacy of Conventional Therapy with Calcium and Activated Vitamin D in Patients with Chronic Post-Operative Hypoparathyroidism: Results of a Cross-Sectional Case-Control Study
por: Mazoni, Laura, et al.
Publicado: (2020)

THU447 Hungry Bone Syndrome Secondary To Denosumab Use In A Patient With Sleeve Gastrectomy
por: Kumar, Arathi Prabha, et al.
Publicado: (2023)

Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study
por: Khan, Aliya, et al.
Publicado: (2021)

SUN-397 The Osteosee System Measurements, Based on Parametric Electrical Impedance Tomography, Correlate with Dual X-Ray Absorptiometry Results for the Diagnosis of Osteoporosis
por: Rouach, Vanessa, et al.
Publicado: (2020)

MON-335 Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?
por: Patel, Reshma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vod2o3d28sfmqh2ubc0v9uosm6